12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fostamatinib disodium: Phase III data

Top-line data from the 12-month, double-blind, international Phase III OSKIRA-1 trial in 923 RA patients who had an inadequate response to methotrexate showed that both regimens of fostamatinib plus methotrexate met the co-primary endpoint of improving ACR20 response rate at week 24 vs. placebo plus methotrexate, but missed the co-primary endpoint of improving mTSS from baseline to week 24 vs. placebo plus methotrexate. Specifically, ACR20 response rate at week 24...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >